76%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
76%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Bayer AG
Closed
SectorFinance
27.065 1.86
Overview
Share price change
24h
Min
26.97
Max
27.09
Income | -1.5B -199M |
|---|---|
Sales | -3B 11B |
P/E Sector Avg | 30.9 26.512 |
EPS | 1.23 |
Profit margin | -1.853 |
Employees | 90,885 |
EBITDA | 1.9B 3.6B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +4.55% upside |
Next Earnings | 11 Nov 2025 |
|---|
Market Cap | -1.8B 25B |
|---|---|
Previous open | 25.21 |
Previous close | 27.065 |
News Sentiment
By Acuity
43%
57%
174 / 535 Finance
Technical Score
By Trading Central
Confidence
Bearish Evidence
Bayer AG Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Bayer AG Forecast
Price Target
By TipRanks
4.55% upside
12 Months Forecast
Average 28.27 EUR 4.55%
High 35 EUR
Low 23 EUR
Based on 13 Wall Street analysts offering 12 month price targets forBayer AG - Dist in the last 3 months.
Sentiment
By Acuity
174 / 535 Finance
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Bayer AG
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
